What is the evidence for the use of GnRH analogues for more than 6 months in treating endometriosis or uterine fibroids?

Tripdatabase
2026 · doi:10.5281/zenodo.21336881 · W7168158345
Review OA: green CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-29 ⓘ

Evidence supports GnRH analogue use for endometriosis and uterine fibroids up to six months, while longer durations require careful management of side effects such as bone health through potential add-back therapies.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-29 · read from full text ⓘ

This review examines the clinical evidence supporting the use of gonadotropin-releasing hormone analogues for durations exceeding six months in patients with endometriosis or uterine fibroids. The authors note that while strong data supports treatment efficacy up to half a year, extended therapy requires careful management of adverse effects, particularly regarding bone mineral density loss. To mitigate these risks, the paper highlights the potential utility of add-back therapies during prolonged administration periods. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Long-term use of GnRH analogues for endometriosis and uterine fibroids is limited, with strong evidence supporting up to 6 months. Longer durations require careful management of side effects, notably bone health, potentially utilizing add-back therapies.
Full text 613 characters · extracted from oa-doi-fallback · click to expand
Published July 13, 2026 | Version v1 Other Open What is the evidence for the use of GnRH analogues for more than 6 months in treating endometriosis or uterine fibroids? Description Long-term use of GnRH analogues for endometriosis and uterine fibroids is limited, with strong evidence supporting up to 6 months. Longer durations require careful management of side effects, notably bone health, potentially utilizing add-back therapies. Files 33de8a9d-1514-4a88-b2f5-3f29a2c79aff.pdf Files (18.5 kB) | Name | Size | Download all | |---|---|---| | md5:1aebb9405bebc71e4baf3f3c0887a5cf | 18.5 kB | Preview Download |

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-10-07T06:01:52.021920+00:00
License: CC0 · commercial use OK